Cansortium Inc (CNTMF) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Cansortium Inc $0.03, price $0.02, upside +7.5%, quality 20 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Cansortium Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
FLUENT Corp., through its subsidiaries, cultivates, manufactures, processes, distributes, and sells medical cannabis products for medical and adult-use in the United States. Its medical cannabis products are offered in oral drops, capsules, topicals, syringes, dried flower, pre-rolls, cartridges, concentrates, and edibles.
Show more
FLUENT Corp., through its subsidiaries, cultivates, manufactures, processes, distributes, and sells medical cannabis products for medical and adult-use in the United States. Its medical cannabis products are offered in oral drops, capsules, topicals, syringes, dried flower, pre-rolls, cartridges, concentrates, and edibles. The company also sells various third-party branded medical cannabis products, as well as other accessories. It offers its products under the Bag-O, FLUENT, Hyer Kind, Knack, MOODS, and Wandr brands. The company was formerly known as Cansortium Inc. and changed its name to FLUENT Corp. in February 2025. FLUENT Corp. was founded in 2015 and is headquartered in Tampa, Florida.
Stock analysis
Cansortium Inc (CNTMF) currently trades at $0.0240, while our model-based Fair Value estimate is $0.0258, implying the stock looks roughly 7.0% fairly valued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 20/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Cansortium Inc reported revenue of $86.7M in FY2025 versus $65.4M in FY2021, a compound +7.3%/yr. Reported net income was −$72.5M in FY2025.
Key figures
Market cap $15.3M · P/S ratio 0.19 · EPS (TTM) $−0.1600 · Net margin −83.6% · Return on equity −534% · Return on assets (EBIT) −0.4% · Operating margin −46.0% · Revenue (TTM) $81.7M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 66% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 8%, CNTMF screens cheaper than that median.
Fair Value models
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.30/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−0.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.6%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.4%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−16.1% (2020) → −17.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks
Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score21 · Bottom 25%
Fair Value upside0% · Above median
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−10% · Bottom 25%
Net margin (TTM)−96% · Bottom 25%
Operating margin (TTM)−46% · Bottom 25%
Growth and dividend
Revenue growth−22% · Bottom 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM)0.20× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)43· sector 15
FUTURE (revenue growth)0· sector 20
PAST (return on equity)0· sector 27
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 32
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Cansortium Inc Fair Value". https://www.fairvalue-calculator.com/stock/CNTMF
Frequently asked questions
Is Cansortium Inc (CNTMF) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.0258 versus a price of $0.0240, about +8% upside (fairly valued).
What is the fair value of CNTMF?
Our model-based fair value for Cansortium Inc is $0.0258 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.0240.
What is the quality score of CNTMF?
Cansortium Inc has a Quality Score of 20/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cansortium Inc (CNTMF)?
Our model-based price target is the fair value of $0.0258 (as of Sep 23, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Cansortium Inc stock forecast for 2026?
Our models put fair value at $0.0258, about +8% upside versus a price of $0.0240 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of Cansortium Inc (CNTMF)?
Cansortium Inc reported trailing-twelve-month revenue of about $81.7M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Cansortium Inc (CNTMF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cansortium Inc it is $0.0258 per share (as of Sep 23, 2026), against a price of $0.0240. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Cansortium Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, CNTMF trades below its calculated fair value: price $0.0240, fair value $0.0258, a gap of about +8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CNTMF?
No. The price is what the market pays today ($0.0240); the fair value is what the company's own numbers justify ($0.0258). For Cansortium Inc the two are $0.0018 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cansortium Inc worth?
The market values Cansortium Inc at about $15.3M (market capitalisation, as of Sep 23, 2026). Per share that is $0.0240; our models calculate a fair value of $0.0258 per share.
How solid is the balance sheet of Cansortium Inc (CNTMF)?
Balance-sheet figures for Cansortium Inc (as of Sep 23, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 20/100, which measures business quality independently of the share price.
How far is CNTMF from its 52-week high?
Cansortium Inc trades at $0.0240, about 66% below its 52-week high of $0.0700 and 20% above the low of $0.0200 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0258 is for.
Which stocks are comparable to Cansortium Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cansortium Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $0.0240, calculated fair value $0.0258 (+8%), Quality Score 20/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CNTMF calculated?
We run Cansortium Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0258, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Cansortium Inc currently trades 8 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cansortium Inc (CNTMF)?
The closing price on Sep 24, 2026 was $0.0240. Our model-based fair value is $0.0258, about +8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cansortium Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Cansortium Inc
How large is the market capitalisation of Cansortium Inc (CNTMF)?
The market capitalisation of Cansortium Inc is $15.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cansortium Inc (CNTMF)?
The price-to-sales ratio of Cansortium Inc is 0.19 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cansortium Inc (CNTMF)?
Earnings per share at Cansortium Inc are $−0.1600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Cansortium Inc (CNTMF)?
The net margin of Cansortium Inc is −83.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cansortium Inc (CNTMF)?
The return on equity (ROE) of Cansortium Inc is −534% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cansortium Inc (CNTMF)?
On an EBIT basis the return on assets of Cansortium Inc is −0.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cansortium Inc (CNTMF)?
The operating margin of Cansortium Inc is −46.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cansortium Inc (CNTMF)?
Revenue at Cansortium Inc is growing −21.9% versus a year earlier (3y avg −0.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Cansortium Inc (CNTMF) generate?
The free cash flow of Cansortium Inc is −$15.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cansortium Inc (CNTMF) carry?
The net debt of Cansortium Inc is $64.0M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Cansortium Inc in the live analysis
One click puts Cansortium Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026